Medicines planning
46 results
Applied filters
New Medicines News
9 April 2026New Medicines News is produced by the SPS Horizon Scanning Service. It highlights recent new product launches and significant medicines regulatory changes.
The licence and supporting evidence for ranibizumab biosimilars
5 November 2025Four licensed ranibizumab biosimilars are available: Byooviz, Ongavia, Rimmyrah and Ximluci. Learn about the licensed indications and supporting evidence
Understanding patents
11 July 2025Patents allow the inventor a finite period of monopoly in exchange for publicising the idea. We explain how they work with respect to medicines.
Preparing to use denosumab 60mg biosimilar
16 January 2026Biosimilars of denosumab 60mg (Prolia) are available. We offer general information and implementation advice.
The licence and supporting evidence for golimumab biosimilar
28 November 2025We highlight evidence for licensed golimumab biosimilar(s) and differences between the biosimilar(s) and the reference product (Simponi).
Primary care discussions: biosimilar insulin
30 September 2025Discussion about the considerations of implementing biosimilar insulin in primary care. Hints and tips for systems considering a move to biosimilar insulin.
Biosimilar and key generic medicines – December 2025 update
10 December 2025An update about biosimilar and key generic medicines to support system planning and mobilisation.
The licence and supporting evidence for denosumab 120mg biosimilars
16 January 2026Denosumab 120mg biosimilars are licensed. Learn about indications, formulations, supporting evidence and differences.
The licence and supporting evidence for denosumab 60mg biosimilars
16 January 2026Denosumab 60mg biosimilars are licensed. Learn about indications, formulations, supporting evidence and differences.
Preparing to use natalizumab biosimilar
6 February 2024Natalizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team.